Skip to main content

Table 3 Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in the FUSCC cohort

From: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

Variablesa OS DFS
Univariate analysis P b Multivariate analysis P b Univariate analysis P b Multivariate analysis P b
HR (95 % CI)   HR (95 % CI)   HR (95 % CI)   HR (95 % CI)  
Age (years)
  ≤ 60 1.000 0.367 1.000 0.564 1.000 0.593 1.000 0.633
  > 60 1.224 (0.789–1.900)   1.154 (0.709–1.879)   1.115 (0.749–1.661)   1.113 (0.717–1.730)
Genderb
 Male 1.000 0.418 1.000 0.493 1.000 0.238 1.000 0.305
 Female 0.829 (0.526–1.306)   0.843 (0.518–1.374)   0.781 (0.518–1.178)   0.793 (0.509–1.235)
Tumor location
 Colon 1.000 0.061    1.000 0.223   
 Rectum 0.658 (0.424–1.020)     0.784 (0.529–1.160)   
Histological type
 Adenocarcinoma 1.000 0.781    1.000 0.765   
 Mucinous/SRCC 0.867 (0.317–2.369)     0.872 (0.355–2.143)   
T stage
 Tis-T2 1.000 <0.001 1.000 0.017 1.000 <0.001 1.000 0.032
 T3 4.450 (0.975–20.312)   6.329 (1.325–30.238)   2.979 (0.971–9.138)   3.471 (1.074–11.221)
 T4 10.534 (2.581–42.992)   8.734 (1.948–39.161)   6.524 (2.390–17.805)   4.282 (1.443–12.710)
N stage
 N0 1.000 <0.001 1.000 0.269 1.000 <0.001 1.000 0.089
 N1 2.770 (1.537–4.992)   2.011 (0.982–4.117)   2.927 (1.721–4.979)   2.251 (1.202–4.215)
 N2 4.146 (2.336–7.357)   1.931 (0.903–4.130)   4.212 (2.510–7.069)   1.968 (0.984–3.934)
M stage
 M0 1.000 <0.001 1.000 0.024 1.000 <0.001 1.000 <0.001
 M1 9.094 (5.757–14.367)   2.833 (1.137–6.083)   10.198 (6.648–15.642)   4.377 (1.999–9.585)
Pathological grading
 Well/moderate 1.000 0.378    1.000 0.729   
 Poor/anaplastic 1.278 (0.762–2.144)     1.137 (0.706–1.832)   
 Unknown 0.576 (0.180–1.836)     0.784 (0.317–1.941)    
Venous invasion
 Negative 1.000 <0.001 1.000 0.987 1.000 <0.001 1.000 0.55
 Positive 2.448 (1.578–3.796)   0.986 (0.578–1.681)   2.216 (1.492–3.291)   0.760 (0.464–1.246)
 Unknown 1.043 (0.143–7.587)   1.163 (0.154–8.756)   0.813 (0.112–5.884)   0.821 (0.110–6.136)
Nervous invasion
 Negative 1.000 0.059    1.000 0.008 1.000 0.199
 Positive 1.641 (0.981–2.743)     1.186 (1.175–2.949)   1.375 (0.846–2.237)
No. of LNs dissected
  < 12 1.000 0.249    1.000 0.297   
  ≥ 12 0.719 (0.410–1.260)     0.757 (0.449–1.276)   
MMR status
 MMR-proficient 1.000 0.726    1.000 0.792   
 MMR-deficient 1.084 (0.692–1.696)     0.947 (0.632–1.418)   
CEA (μl/ml)
  ≤ 5 1.000 <0.001 1.000 0.041 1.000 <0.001 1.000 0.096
  > 5 2.468 (1.572–3.875)   1.386 (0.824–2.331)   2.768 (1.845–4.152)   1.529 (0.956–2.444)
 Unknown 2.850 (1.118–7.265)   3.513 (1.292–9.558)   2.472 (0.979–6.246)   2.230 (0.848–5.863)
Adjuvant chemotherapy
 Yes 1.000 <0.001 1.000 0.019 1.000 <0.001 1.000 0.366
 No 0.670 (0.315–1.425)   1.835 (0.735–4.584)   0.568 (0.281–1.146)   1.419 (0.609–3.307)
 Unknown 8.344 (5.142–13.542)   3.130 (1.345–7.282)   6.990 (4.495–10.870)   1.645 (0.755–3.584)
TILs-PD-1
 Low 1.000 0.007 1.000 0.006 1.000 0.003 1.000 0.015
 High 0.500 (0.302–0.828)   0.480 (0.283–0.814)   0.502 (0.319–0.789)   0.559 (0.350–0.893)
TCs-PD-L1
 Low 1.000 0.027 1.000 0.852 1.000 0.005 1.000 0.66
 High 0.606 (0.389–0.944)   1.048 (0.639–1.719)   0.558 (0.373–0.835)   0.904 (0.577–1.417)
  1. aAll variables are djusted by Cox proportional hazards models including age, gender, T stage, N stage and M stage
  2. bItalic entries indicate statistical significance